ryo

If you contract seasonal influenza, you have the right to take leave from work. However, this is generally recognized not as a "legally mandated prohibition of attendance," but as a right to voluntary rest to protect your health, and an accommodation based on the company's duty of care for safety.As of 2025, the Labor Standards Act (LSA) does not specify compulsory attendance restrictions unique to influenza. However, in the interest of preventing the spread of infection, many companies establish rules referencing the standards of the School Health and Safety Act. Below is a summary of the relevant LSA provisions and key company rules, based on MHLW/Japanese Association for Infectious Diseases guidelines and practical case studies.

Based on a thorough analysis of 2025 real-world data (National Institute of Infectious Diseases, MHLW, as of November) comparing individuals who experienced co-infection versus those who avoided it, the following preventive measures are ranked by their proven efficacy.

Co-infection with Influenza and COVID-19, commonly known as "Flurona," has been confirmed in approximately 1,200 cases nationwide in Japan (as of November) and poses a severity risk incomparable to single-pathogen infections. Latest national data (MHLW, NIID) reveals that Flurona elevates the risk of hospitalization by 4−6 times and the mortality risk by up to 15 times. This article thoroughly compares the real danger of co-infection and the decisive differences in symptoms, based on the predominant strains in 2025. It is crucial to understand the worst-case scenario—the simultaneous onset of "Influenza's rapid high fever" and "COVID's breathlessness and persistent cough"—and to take action immediately upon symptom onset.

This summary provides the actual incidence rates and comprehensive management strategies for influenza vaccine side effects, based on the latest reports from the Ministry of Health, Labour and Welfare, PMDA data, and the Japanese Association for Infectious Diseases summary, covering the period from October 2025 to the present.

Based on 2024-2025 seasonal data in Japan and the latest guidelines (Japanese Association for Infectious Diseases, Japan Society of Obstetrics and Gynecology, and MHLW 2025 Revision), this summary focuses on the severe illness risks and specific countermeasures for the elderly (aged 65 and over) and pregnant women.

The treatment for influenza (Type A and B) is primarily categorized into two classes of drugs: neuraminidase inhibitors (e.g., Tamiflu, Relenza) and endonuclease inhibitors (Xofluza). Based on the guidelines from the Japanese Association for Infectious Diseases and the Ministry of Health, Labour and Welfare, early administration within 48 hours of onset is recommended, and is expected to shorten the duration of symptoms by 1 to 2 days. For high-risk patients (elderly, those with underlying conditions, pregnant women), emphasis is also placed on the effect of preventing severe illness. The focus of this summary will be on Tamiflu (Oseltamivir), Xofluza (Baloxavir), and Nasal Sprays (Relenza).